Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,078 matching trials from the live ClinicalTrials.gov search.
Conditions
Lymphoma, Multiple Myeloma
Interventions
Spiritual Therapy, Best Practice
Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Acute Suicidal Depression (ASD)
Interventions
Subanesthetic dose intravenous ketamine (KET), Electroconvulsive therapy (ECT)
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
9
States / cities
San Francisco, California • Baltimore, Maryland • Belmont, Massachusetts + 6 more
Conditions
Acute Kidney Injury
Interventions
Level A, Level B, Passive Alert
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Altoona, Pennsylvania • Farrell, Pennsylvania • McKeesport, Pennsylvania + 3 more
Completed No phase listed Observational Accepts healthy volunteers

The Severe Asthma Research Program III-Boston Clinical Site

NCT01761630
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Elliot Israel, MD
Other
Eligibility
6 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Intergenerational Reminiscence and Digital Storytelling

NCT05984732
Conditions
Alzheimer Disease
Interventions
Reminiscence with digital storytelling, Social wellness with scrapbook or journal
Behavioral
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
65 Years and older
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Arlington, Texas
Conditions
Human Immunodeficiency Virus
Interventions
Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
145
States / cities
Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more
Completed Not applicable Interventional

Mood and Thought Process Study

NCT05585775
Conditions
Depression in Remission, Depressive Symptoms, Depression
Interventions
Mindfulness-Based Cognitive Therapy, Wellness for Wellbeing
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Withdrawn Early Phase 1 Interventional

S-Nitrosylation Therapy of COVID-19

NCT04528771
Conditions
SARS-CoV2 Infection, Covid19
Interventions
SNO, Nitrogen gas
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Accepts healthy volunteers

Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients

NCT02428244
Conditions
Smoking, Tobacco, Fractures, Bone
Interventions
Motivational Interviewing, Motivational Interviewing + Follow-up
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 79 Years
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Active, not recruiting Not applicable Interventional

Sodium Lowering Vascular Effects Trial

NCT05388032
Conditions
Endothelial Dysfunction, Vascular Stiffness, Left Ventricular Hypertrophy, Left Ventricular Dysfunction
Interventions
Sodium Reduction Intervention
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
Interventions
BGB-A3055, Tislelizumab, Chemotherapy
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Orlando, Florida • Iowa City, Iowa • Hackensack, New Jersey + 3 more
Conditions
Invasive Mold Infections
Interventions
Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 15 more
Conditions
Heart Failure, Heart Failure, Systolic
Interventions
Pharmacist/Cardiologist Virtual Team Digital Consultation
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Bipolar Disorder
Interventions
Nutrition, Exercise, and Wellness (NEW) psychotherapy, Typically consists of at least one FDA-approved mood stabilizer
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Quality IQ Patient Simulation Physician Practice Measurement and Engagement

NCT03800901
Conditions
Diabetes, Hypertension, Depression, Osteoarthritis, Asthma, Pain, Heart Failure
Interventions
Continuing Medical Education, Quality IQ Patient Simulations
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
Pulmonary Emphysema
Interventions
Treatment plus Optimal Medical Therapy, Optimal Medical Therapy
Device · Other
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Conditions
Atrial Fibrillation, Arrhythmias, Cardiac
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
San Diego, California
Conditions
Lymphoma Leukemia
Interventions
allogeneic CAR19 regulatory T cells (CAR19-tTreg), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly, Gait Disorders
Interventions
Walkasins, Fall Prevention Training
Device · Other
Lead sponsor
RxFunction Inc.
Industry
Eligibility
55 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Mesa, Arizona • Boston, Massachusetts • Saint Paul, Minnesota + 3 more
Conditions
Asthma
Interventions
ASMAS, Asthma education plus child health
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
11 Years to 14 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Conditions
Shoulder Pain, Neck Pain
Interventions
Noxipoint Therapy, Physical Therapy
Procedure
Lead sponsor
Pain Cure Center, California
Industry
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Cancer Metastatic, Symptoms and Signs, Quality of Life
Interventions
Symptom Management and Survivorship Handbook + Coaching, Symptom Management and Survivorship Handbook
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona